NEW YORK, June 9 (GenomeWeb News) - In another step of its ongoing reorganization, Applied Biosystems is selling its Texas-based mass spectrometry manufacturing facility to Delphi Medical Systems, a multi-faceted instrument manufacturer, according to people familiar with the transaction.
The deal, which was to have closed on June 6, will be announced June 9, according to one of these individuals.
Financial terms of the deal or the status of the employees were not immediately known.
A spokesperson for ABI confirmed the sale, but did not elaborate. She referred a GenomeWeb News reporter to a second spokesperson, who did not immediately return a telephone call seeking comment.
The sale of the facility is consistent with an ongoing restructuring at ABI, especially in its proteomic instrument business. Last September, the company transferred its Voyager MALDI-TOF and 4700 MALDI-TOF/TOF instruments, made in
R&D and manufacturing of the Voyager and 4700 mass spectrometers --- the only ones that ABI manufactured in-house at the time --- and related intellectual property will be moved to the ABI/MDS Sciex Instruments joint venture in
As part of that deal, manufacturing will move from ABI's facility to MDS Sciex. In addition, ABI has reduced its MALDI R&D group in
Delphi Medical Systems, based in